ERYTECH receives authorization to start its Phase II clinical study in pancreatic cancer Post author:admERY Post published:May 6, 2014 Post category:Newsroom ERYTECH announces that the ANSM, French healthcare agency, has granted the authorization to start a Phase II study in second line treatment of patients affected by pancreatic cancer. You Might Also Like ERYTECH to Participate in the Upcoming April Investor Conferences March 28, 2022 ERYTECH to Hold Q3 2016 Business Update Conference Call on November 4th, 2016 October 26, 2016 ERYTECH Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases February 8, 2022